secwatch.observer — SEC 8-K summary
======================================

Issuer:     Equillium, Inc. (EQ)
CIK:        0001746466
Form:       8-K
Filed at:   2026-05-13T20:05:19+00:00
Accession:  0001193125-26-221595
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Equillium Q1 net loss narrows to $5.3M; EQ504 Phase 1 on track for mid-2026
---------------------------------------------------------------------------

- Q1 net loss of $5.3M ($0.06/sh) vs. $8.7M ($0.24/sh) in Q1 2025; R&D spending down to $3.0M.
- Cash and equivalents $61.3M as of March 31, 2026; funded into 2029; includes $35M March private placement.
- Phase 1 proof-of-mechanism study of EQ504 (AhR modulator) on track for mid-2026, data ~6 months later.
- Appointed Snehal Naik, Ph.D., as Chief Development Officer; she brings >15 years immunology experience.
- Evaluating further advancement of EQ302 (IL-15/IL-21 inhibitor) for GI indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746466/000119312526221595/0001193125-26-221595-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746466/000119312526221595/eq-20260513.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-221595

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer